Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
PolyPeptide is a leading global CDMO specializing in peptide and oligonucleotide-based active pharmaceutical ingredients (APIs) with over 70 years of experience. The company operates six GMP-certified manufacturing facilities across Europe, the United States, and India. It offers end-to-end services from pre-clinical development through Phase III clinical trials to commercial manufacturing. PolyPeptide has manufactured over 1,000 GMP-grade peptides and maintains a pipeline of 196 active custom projects as of 2021, with 30 in Phase III. Revenue grew 26.5% in 2021 to EUR 282.1 million.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on PolyPeptide Laboratories (Sweden).